[
    [
        {
            "time": "",
            "original_text": "【上海医药】年报点评：研发投入大幅增长，商业网络继续完善",
            "features": {
                "keywords": [
                    "上海医药",
                    "年报",
                    "研发投入",
                    "大幅增长",
                    "商业网络",
                    "完善"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【上海医药】年报点评：研发投入大幅增长，商业网络继续完善",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "创新疫苗将进入第二波浪潮，重新梳理长期医药十年十倍四大主线【国盛医药张金洋团队】",
            "features": {
                "keywords": [
                    "创新疫苗",
                    "第二波浪潮",
                    "长期医药",
                    "十年十倍",
                    "四大主线",
                    "国盛医药",
                    "张金洋团队"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "创新疫苗将进入第二波浪潮，重新梳理长期医药十年十倍四大主线【国盛医药张金洋团队】",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]